<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Medicina Regenerativa &#187; COMPARE-AMI</title>
	<atom:link href="https://temas.sld.cu/medicinaregenerativa/tag/compare-ami/feed/" rel="self" type="application/rss+xml" />
	<link>https://temas.sld.cu/medicinaregenerativa</link>
	<description>Sitio de la red de salud de Cuba sobre Medicina Regenerativa</description>
	<lastBuildDate>Wed, 06 Dec 2023 04:32:56 +0000</lastBuildDate>
	<language>es-ES</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	
	<item>
		<title>One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133+ Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction.S Mansour.Bone Marrow Research 2011</title>
		<link>https://temas.sld.cu/medicinaregenerativa/2011/10/09/one-year-safety-analysis-of-the-compare-ami-trial-comparison-of-intracoronary-injection-of-cd133-bone-marrow-stem-cells-to-placebo-in-patients-after-acute-myocardial-infarction-and-left-ventricular/</link>
		<comments>https://temas.sld.cu/medicinaregenerativa/2011/10/09/one-year-safety-analysis-of-the-compare-ami-trial-comparison-of-intracoronary-injection-of-cd133-bone-marrow-stem-cells-to-placebo-in-patients-after-acute-myocardial-infarction-and-left-ventricular/#comments</comments>
		<pubDate>Sun, 09 Oct 2011 16:49:48 +0000</pubDate>
		<dc:creator><![CDATA[medicinaregenerativa]]></dc:creator>
				<category><![CDATA[Publicaciones internacionales]]></category>
		<category><![CDATA[COMPARE-AMI]]></category>

		<guid isPermaLink="false">http://articulos.sld.cu/medregenerativa/?p=1578</guid>
		<description><![CDATA[Abstract Bone marrow stem cell therapy has emerged as a promising approach to improve healing of the infarcted myocardium. Despite initial excitement, recent clinical trials using non-homogenous stem cells preparations showed variable and mixed results. Selected CD133+ hematopoietic stem cells are candidate cells with high potential. Herein, we report the one-year safety analysis on the [&#8230;]]]></description>
		<wfw:commentRss>https://temas.sld.cu/medicinaregenerativa/2011/10/09/one-year-safety-analysis-of-the-compare-ami-trial-comparison-of-intracoronary-injection-of-cd133-bone-marrow-stem-cells-to-placebo-in-patients-after-acute-myocardial-infarction-and-left-ventricular/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
